Abstract | STUDY OBJECTIVE: DESIGN: Multicenter, double-blind, randomized, placebo-controlled study. PATIENTS: INTERVENTIONS: Following a 2-week run-in period, while pulmonary function, sputum production, and mucociliary function were assessed, patients were assigned to receive seratrodast, 40 mg/d, or placebo for 6 weeks. MEASUREMENTS AND RESULTS: During the treatment period, the changes in FEV(1) and peak expiratory flow (PEF) were not different between the two patient groups, but there were significant reductions in diurnal variation of PEF (p = 0.034), frequency of daytime asthma symptoms (p = 0.030), and daytime supplemental use of beta(2)-agonist (p = 0.032) in the seratrodast group. For sputum analysis, seratrodast treatment decreased the amount of sputum (p = 0.005), dynamic viscosity (p = 0. 007), and albumin concentration (p = 0.028), whereas it had no effect on elastic modulus or fucose concentration. Nasal clearance time of a saccharin particle was shortened in the seratrodast group at week 4 (p = 0.031) and week 6 (p = 0.025), compared with the placebo group. CONCLUSION: Blockade of TxA(2) receptor has minimal effects on pulmonary function, but may cause an improvement in mucociliary clearance by decreasing the viscosity of airway secretions.
|
Authors | J Tamaoki, M Kondo, J Nakata, Y Nagano, K Isono, A Nagai |
Journal | Chest
(Chest)
Vol. 118
Issue 1
Pg. 73-9
(Jul 2000)
ISSN: 0012-3692 [Print] United States |
PMID | 10893362
(Publication Type: Clinical Trial, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Anti-Asthmatic Agents
- Benzoquinones
- Heptanoic Acids
- seratrodast
|
Topics |
- Adult
- Aged
- Anti-Asthmatic Agents
(pharmacology)
- Asthma
(physiopathology)
- Benzoquinones
(pharmacology)
- Double-Blind Method
- Heptanoic Acids
(pharmacology)
- Humans
- Middle Aged
- Mucociliary Clearance
(drug effects)
- Respiratory Mechanics
- Sputum
(chemistry, metabolism)
- Viscosity
|